Haleos Labs Limited (HALEOSLABS) — shareholding pattern, promoter holding, financials and share price
About Haleos Labs Limited (HALEOSLABS)
Haleos Labs Limited operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as HALEOSLABS and on the BSE under scrip code 540679. Its ISIN is INE320X01016.
Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates [1]
SMS Lifesciences India Limited is primarily involved in the manufacturing and export of Active Pharmaceutical Ingredients (APIs) and their intermediates. The company operates multiple facilities across Hyderabad.
Originally incorporated as a real estate private limited company in 2006, SMS Lifesciences has undergone several transformations, including demergers and acquisitions.
Listed peers in Pharmaceuticals: Zim Laboratories Ltd, Jenburkt Pharmaceuticals Ltd, Bafna Pharmaceuticals Ltd, Transchem Ltd, Albert David Ltd, Aptus Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹1,654.99 a share on 10 Jul 2026, Haleos Labs Limited (HALEOSLABS) was valued at a price-to-earnings ratio of 28.11x against an industry P/E of 36.41x and a price-to-book of 2.55x on a book value of ₹650.15 per share as of Mar 2025. Solomo computes return on equity of 9.06% and return on capital employed of 11.18% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 28.11x
- Industry P/E
- 36.41x
- P/B
- 2.55x
- EPS (TTM)
- ₹58.88
- Book value / share
- ₹650.15
- ROE
- 9.06%
- ROCE
- 11.18%
- ROA
- 4.56%
- Debt / equity
- 0.44x
- Dividend yield
- 0.18%
- EBITDA margin
- 14.11%
- 52-week range
- ₹1,050.05 – ₹1,778.35
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Haleos Labs Limited (HALEOSLABS) reported revenue of ₹334 crore, net profit of ₹18 crore and earnings per share of ₹57.26. That compares with revenue of ₹345 crore and net profit of ₹19 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹75.14 crore and net profit ₹0.35 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 350 | 316 | 306 | 345 | 334 |
| Net profit (₹ cr) | 25 | 11 | 6 | 19 | 18 |
| EPS (₹) | 83.75 | 37.91 | 30.07 | 66.52 | 57.26 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 5.44% | -0.96% | 12.67% |
| Profit growth | 18.50% | -5.57% | 195.89% |
| Stock price CAGR | 16% | 46% | 22% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 72.11% of Haleos Labs Limited (HALEOSLABS) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.31%. Market capitalisation was ₹500 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2017.
Largest disclosed public shareholders in Jun 2026: HARITA PROJECTS PRIVATE 1.76%, S VIJAYAKUMAR 1.11%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 72.11% | - | - | 0.31% | 27.89% |
| Mar 2026 | 72.11% | - | - | 0.3% | 27.89% |
| Dec 2025 | 71.8% | - | - | 0.29% | 28.2% |
| Sep 2025 | 71.41% | - | - | 0.03% | 28.59% |
| Jun 2025 | 71.41% | - | 0.03% | - | 28.59% |
| Mar 2025 | 71.41% | - | - | - | 28.59% |
| Dec 2024 | 71.41% | - | - | - | 28.59% |
| Sep 2024 | 71.41% | - | 0.02% | - | 28.59% |